Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synthetic method of linagliptin

A synthetic method, methyl technology, applied in the production of bulk chemicals, organic chemistry, etc., can solve problems such as amide bond breakage, and achieve the effects of environmental protection, high purity, and slow filtration speed

Active Publication Date: 2016-09-14
赤峰赛林泰药业有限公司
View PDF9 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since hydrochloric acid is a strong acid, it is easy to cause the amide bond in the intermediate (g) and listagliptin to break

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthetic method of linagliptin
  • Synthetic method of linagliptin
  • Synthetic method of linagliptin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] The method for preparing formula g compound linagliptin, it may further comprise the steps:

[0060] (1) Synthesis of intermediate (c)

[0061] Reaction of 8-bromo-3-methylxanthine (a) with 1-bromo-2-butyne (b) affords intermediate (c).

[0062]

[0063] Operation steps: Add 908g (3.7mol) 8-bromo-3-methylxanthine (a), 574.1g (4.442mol) N,N-diisopropylethylamine (DIEA) into a 2L three-necked flask, 591.1 g (4.445 mol) of 1-bromo-2-butyne (b), 12 L of acetone. Start stirring, heat to reflux reaction, and the reaction ends after 4-6 hours. The reaction solution was cooled to room temperature, filtered with suction, and the filter cake was washed with 4 L of methanol to obtain a pale yellow solid, which was dried to obtain 1013.7 g of the product with a purity of 95.7% and a yield of 105.9%.

[0064] (2) Synthesis of intermediate (e)

[0065] Intermediate (c) is reacted with 2-chloromethyl-4-methylquinazoline (d) to give intermediate (e).

[0066]

[0067] Operat...

Embodiment 2

[0080] The method for preparing formula g compound linagliptin, it may further comprise the steps:

[0081] (1) Synthesis of intermediate (c)

[0082] Reaction of 8-bromo-3-methylxanthine (a) with 1-bromo-2-butyne (b) affords intermediate (c).

[0083]

[0084] Operation steps: Add 36.75g (0.15mol) 8-bromo-3-methylxanthine (a), 23.26g (0.18mol) N,N-diisopropylethylamine (DIEA) into a 500mL three-necked flask , 21.94g (0.165mol) 1-bromo-2-butyne (b), acetone 350mL. Start stirring, heat to reflux reaction, and the reaction ends after 7h. The reaction solution was cooled to room temperature, filtered with suction, and the filter cake was washed with 100 mL of methanol to obtain a pale yellow solid, which was dried to obtain 52.96 g of the product with a purity of 92.0% and a yield of 118.8%.

[0085] (2) Synthesis of intermediate (e)

[0086] Intermediate (c) is reacted with 2-chloromethyl-4-methylquinazoline (d) to give intermediate (e).

[0087]

[0088] Operation st...

Embodiment 3

[0098] The method for preparing formula g compound linagliptin, it may further comprise the steps:

[0099] (1) Synthesis of intermediate (c)

[0100] Reaction of 8-bromo-3-methylxanthine (a) with 1-bromo-2-butyne (b) affords intermediate (c).

[0101]

[0102] Operation steps: In a 500mL three-necked flask, add 10g (0.04mol) 8-bromo-3-methylxanthine (a), 6.2g (0.048mol) N,N-diisopropylethylamine (DIEA), 6.9g (0.052mol) of 1-bromo-2-butyne (b), 120mL of acetone. Start stirring, heat to reflux reaction, and the reaction ends after 5.5h. The reaction solution was cooled to room temperature, filtered with suction, and the filter cake was washed with 50 mL of methanol to obtain a pale yellow solid, which was dried to obtain 12.9 g of the product with a purity of 93.6 and a yield of 106.3%.

[0103] (2) Synthesis of intermediate (e)

[0104] Intermediate (c) is reacted with 2-chloromethyl-4-methylquinazoline (d) to give intermediate (e).

[0105]

[0106] Operation steps...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a synthetic method of linagliptin, wherein the method includes the following steps: (1) carrying out a reaction of 8-bromo-3-methylxanthine (a) and 1-bromo-2-butyne (b), to obtain 3-methyl-7-(2-butyne-1-yl)-8-bromo-xanthine (c); (2) carrying out a reaction of 3-methyl-7-(2-butyne-1-yl)-8-bromo-xanthine (c) and 2-chloromethyl-4-methylquinazoline (d), to obtain 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyne-1-yl)-8-bromoxanthine (e); (3) adding 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyne-1-yl)-8-bromoxanthine (e), (R)-3-Boc-aminopiperidine (f), potassium carbonate and acetonitrile into a reactor and mixing evenly, and carrying out a reaction under a state of heating reflux, to obtain t-butyloxycarboryl-linagliptin (g); and (4) removing a Boc protective group of t-butyloxycarboryl-linagliptin (g) in a methanol aqueous solution, to obtain linagliptin. The synthetic method has the advantages of environmental protection, no pollution, high production rate, and no impurities.

Description

technical field [0001] The invention relates to a synthetic method of linagliptin. Background technique [0002] Currently, several DPP-4 inhibitors have been approved for the treatment of T2DM patients. Linagliptin (linagliptin) is one of the new members. Linagliptin is an 8-(3-aminopiperidine)-xanthine derivative designed and synthesized by Boehringer Ingelheim (WO 2004018468 / CN 1675212), which is a DPP-4 inhibitor with strong activity (IC50= 1nmol / L), has the characteristics of high selectivity, long-acting and oral effectiveness, and has good safety and tolerance. [0003] In May 2011, it was approved for marketing by the US FDA, and in June 2011, it was approved for marketing in Europe. In October 2010, Linagliptin was approved in Europe as a combination therapy drug for insulin in patients with T2DM. In April 2013, Linagliptin obtained the Import Drug Registration Certificate issued by China Food and Drug Administration (CFDA), and was approved to be marketed in Ch...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D473/04
CPCY02P20/55C07D473/04
Inventor 崔玉杰张丽华赵宏伟王艳峰季丽萍盛丽王洁婷马征
Owner 赤峰赛林泰药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com